TAS 108;SR 16234;TAS-108 citrate;)-21-[4-[(Diethylamino)methyl]-2-methoxyphenoxy]-7-methyl-19-norpregna-1,3,5(10)-trien-3-ol2-Hydroxy-1,2,3-propanetricarboxylateSalt(1:1);(7α)-21-[4-[(Diethylamino)methyl]-2-methoxyphenoxy]-7-methyl-19-norpregna-1,3,5(10)-trien-3-ol 2-Hydroxy-1,2,3-propanetricarboxylate Salt (1:1);(7±)-21-[4-[(Diethylamino)methyl]-2-methoxyphenoxy]-7-methyl-19-norpregna-1,3,5(10)-trien-3-ol 2-Hydroxy-1,2,3-propanetricarboxylate Salt (1:1)
(7α)-21-[4-[(Diethylamino)methyl]-2-methoxyphenoxy]-7-methyl-19-norpregna-1,3,5(10)-trien-3-ol 2-Hydroxy-1,2,3-propanetricarboxylate Salt (1:1) is a reactant for the preparation of TAS-108, a novel steroidal antiestrogen that exhibits antitumor activity against tamoxifen-resistant breast cancer cell lines.
